Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,

Slides:

Advertisements

Similar presentations

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Advertisements

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma Kimberly S. Grant, MD,

Phase II Study of Preoperative Pemetrexed, Carboplatin, and Radiation Followed by Surgery for Locally Advanced Esophageal Cancer and Gastroesophageal.

Stephen R. Broderick, MD, MPHS

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer Raja Flores, MD, Thomas Bauer, MD, Ralph.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer Marco Alifano, MD, PhD, Pierre.

Don't look now! Risk stratify first

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Puja Gaur, MD, Tsuyoshi Kaneko, MD, Siobhan McGurk, BS, James D

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: A population-based Scandinavian Sarcoma Group study of 106 patients Björn.

Preoperative mediastinoscopic assessment of N factors and the need for mediastinal lymph node dissection in T1 lung cancer Takeshi Funatsu, MD, Yoshito.

Periodic pharyngolaryngoscopy detects early head and neck cancer and improves survival in esophageal cancer Akihito Watanabe, MD, Masao Hosokawa, MD,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Esophageal Resection for Cancer of the Esophagus: Long-Term Function and Quality of Life Allison J McLarty, MD, Claude Deschamps, MD, Victor F Trastek,

Survival after resection of synchronous non–small cell lung cancer

Anthony W. Kim, MD, Robert J. Korst, MD, Jeffrey L. Port, MD, Nasser K

Sex-associated differences in survival of patients undergoing resection for lung cancer Mark K Ferguson, MD, Jun Wang, MD, Philip C Hoffman, MD, Daniel.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Long-term patient and allograft outcomes of renal transplant recipients undergoing cardiac surgery Rodolfo V. Rocha, MD, Diana Zaldonis, MPH, Vinay Badhwar,

The influence of preoperative weight loss on the postoperative course after esophageal cancer resection Maartje K. van der Schaaf, MD, Hugo W. Tilanus,

How should we treat air leaks?

One-year results of thoracic endovascular aortic repair for blunt thoracic aortic injury (RESCUE trial) Ali Khoynezhad, MD, PhD, FACS, Carlos E. Donayre,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Esophagectomy versus endoscopic resection for patients with early-stage adenocarcinoma: Mercedes versus Tesla Toni Lerut, MD The Journal of Thoracic.

Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma Paul C. Lee, MD, Farooq M. Mirza, MD, Jeffrey.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Support Your Specialty

It's not “just a shunt” but sometimes it should be…

Stephen R. Broderick, MD, MPHS

Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: Data from the Surveillance Epidemiology.

Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and.

A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: Initial results Manjit S. Bains, MDa, Alexander Stojadinovic,

Michael Lanuti, MD The Journal of Thoracic and Cardiovascular Surgery

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Mark K. Ferguson, MD, Amy E. Durkin, MS, PA-C

It’s All in the “Swerve of the Curve”

Preoperative Chemotherapy Does Not Increase Complications After Nonsmall Cell Lung Cancer Resection Emilie Perrot, MD, Benoit Guibert, MD, Pierre Mulsant,

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial Nasser.

Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer:

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Topotecan and Paclitaxel in Previously Treated Patients with Relapsed Small Cell Lung Cancer: Phase II Trial of the North Central Cancer Treatment Group

Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma Kimberly S. Grant, MD,

Patients with unbalanced atrioventricular canal defects can undergo the Fontan operation with good outcomes Sitaram M. Emani, MD The Journal of Thoracic.

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

The future of cardiac surgery training: A survival guide

Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices Forum Kamdar, MD, Ranjit John,

“The more things change…”: The challenges ahead

Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials Chi-Fu Jeffrey Yang, MD, Matthew G. Hartwig, MD,

Ryan R. Davies, MD The Journal of Thoracic and Cardiovascular Surgery

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Preoperative PFTs: The answer is blowing in the wind

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Proceed with caution: The importance of surveillance in patients with pathologic complete response after chemoradiation therapy plus surgery for esophageal.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier, MD, R.J Korst, MD, N.K Altorki, MD The Journal of Thoracic and Cardiovascular Surgery Volume 126, Issue 5, Pages 1603-1608 (November 2003) DOI: 10.1016/S0022-5223(03)00710-4

Figure 1 Kaplan-Meier survival for all patients. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 1603-1608DOI: (10.1016/S0022-5223(03)00710-4)

Figure 2 Kaplan-Meier survival for patients undergoing resection. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 1603-1608DOI: (10.1016/S0022-5223(03)00710-4)